Wire flash
US FTC sues Hims & Hers for sharing user health data with Meta and Snap
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
The U.S. Federal Trade Commission (FTC), along with Los Angeles County and Utah, filed a lawsuit against telehealth platform Hims & Hers on July 29, 2026. The lawsuit alleges that Hims & Hers shared users' sensitive health information with online advertising companies, including Meta Platforms and Snap, despite promising privacy. The FTC also accused the company of deceptive billing practices, charging users for prescriptions before they had a consultation with a healthcare provider, and making it difficult to cancel subscriptions. Hims & Hers, a major player in the weight loss drug market and provider of telehealth services for erectile dysfunction, hair loss, and mental health, saw its stock drop approximately 12% following the news. The company denied the allegations, calling them baseless and an effort to generate headlines.
Source report
By Jody Godoy Wed, July 29, 2026 at 9:34 AM PDT | 1 min read
Overview
The U.S. Federal Trade Commission (FTC) has filed a lawsuit against Hims & Hers, alleging that the telehealth platform shared users' sensitive health information with online advertisers—including Meta Platforms and Snap—despite promising privacy. The complaint also accuses the company of deceptive billing and cancellation practices.
The lawsuit was filed jointly with Los Angeles County and the state of Utah.
Key Allegations
- Data Sharing: Hims & Hers allegedly transmitted users' health data to advertising companies, contradicting its public assurances of data privacy.
- Deceptive Billing: The FTC claims the company began charging users for prescriptions before they had a chance to consult with healthcare providers.
- Cancellation Obstruction: The agency also alleges that Hims & Hers made it difficult for customers to cancel their subscriptions.
According to the FTC, most customers do not receive a consultation with a provider and are charged for prescriptions shortly after completing an intake form.
Market Impact
Following the announcement, Hims & Hers stock extended its losses, trading down approximately 12%.
Company Background
Hims & Hers is one of the largest telehealth providers in the weight loss drug market. The company offers telehealth appointments and prescriptions for erectile dysfunction, hair loss, and mental health medications, which are shipped directly to customers.
Official Statements
Christopher Mufarrige, Director of the FTC's Bureau of Consumer Protection, said:
"The FTC will not hesitate to act on behalf of consumers deprived of their ability to choose which products they want and whether to keep their most sensitive health information private."
Hims & Hers responded on social media platform X, calling the claims baseless:
"This is not enforcement grounded in consumer protection; it is an effort to generate headlines at our expense."
Reporting by Jody Godoy in New York; Editing by Chizu Nomiyama and Chris Sanders
Source
Yahoo FinanceWestern
Part of this Story
US FTC Sues Hims & Hers Over Health Data Sharing and Billing Practices